Effects of altered FcγR binding on antibody pharmacokinetics in cynomolgus monkeys

mAbs

Volumn 5, Issue 6, 2013, Pages 896-903

  Leabman, Maya K ^a   Meng, Y Gloria ^a   Kelley, Robert F ^a   DeForge, Laura E ^a   Cowan, Kyra J ^a   Iyer, Suhasini ^a  

^a GENENTECH INC   (United States)

Author keywords

Afucosylation; Aglycosylation; Antibody; Fc R binding; Pharmacokinetics

Indexed keywords

ANTIBODY; FC RECEPTOR; GD ANTIBODY; LT ALPHA ANTIBODY; OX40L ANTIBODY; TRASTUZUMAB; UNCLASSIFIED DRUG; X ANTIBODY; Y ANTIBODY; MONOCLONAL ANTIBODY; PROTEIN BINDING;

AMINO ACID SUBSTITUTION; ANTIGEN BINDING; AREA UNDER THE CURVE; ARTICLE; BINDING AFFINITY; BINDING SITE; CHO CELL; COMPLEMENT DEPENDENT CYTOTOXICITY; DRUG CLEARANCE; DRUG HALF LIFE; ENZYME LINKED IMMUNOSORBENT ASSAY; ESCHERICHIA COLI; FUCOSYLATION; GLYCOSYLATION; HUMAN; IN VITRO STUDY; MACACA FASCICULARIS; NONHUMAN; RECEPTOR BINDING; RETROSPECTIVE STUDY; ANIMAL; DOSE RESPONSE; GENETIC VARIABILITY; GENETICS; HAMSTER; METABOLISM;

ANIMALS; ANTIBODIES, MONOCLONAL; CRICETINAE; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENETIC VARIATION; MACACA FASCICULARIS; PROTEIN BINDING; RECEPTORS, FC;

EID: 84889853699     PISSN: 19420862     EISSN: 19420870     Source Type: Journal    
DOI: 10.4161/mabs.26436     Document Type: Article

References (39)

1. Reichert JM. Marketed therapeutic antibodies compendium. MAbs 2012; 4:413-5; PMID:22531442; http://dx.doi.org/10.4161/mabs.19931
2. Jefferis R. Glycosylation as a strategy to improve antibody-based therapeutics. Nat Rev Drug Discov 2009; 8:226-34; PMID:19247305; http://dx.doi.org/10.1038/nrd2804
3. Deng R, Jin F, Prabhu S, Iyer S. Monoclonal antibodies: what are the pharmacokinetic and pharmacodynamic considerations for drug development? Expert Opin Drug Metab Toxicol 2012; 8:141-60; PMID:22248267; http://dx.doi.org/10. 1517/17425255.2012.643868
4. Edelman GM, Cunningham BA, Gall WE, Gottlieb PD, Rutishauser U, Waxdal MJ. The covalent structure of an entire gammaG immunoglobulin molecule. Proc Natl Acad Sci U S A 1969; 63:78-85; PMID:5257969; http://dx.doi.org/10.1073/ pnas.63.1.78
5. Shields RL, Namenuk AK, Hong K, Meng YG, Rae J, Briggs J, Xie D, Lai J, Stadlen A, Li B, et al. High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R. J Biol Chem 2001; 276:6591-604; PMID:11096108; http://dx.doi.org/10.1074/jbc.M009483200
6. Arnold JN, Wormald MR, Sim RB, Rudd PM, Dwek RA. The impact of glycosylation on the biological function and structure of human immunoglobulins. Annu Rev Immunol 2007; 25:21-50; PMID:17029568; http://dx.doi.org/10.1146/ annurev.immunol.25.022106.141702
7. Shields RL, Lai J, Keck R, O'Connell LY, Hong K, Meng YG, Weikert SH, Presta LG. Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity. J Biol Chem 2002; 277:26733-40; PMID:11986321; http://dx.doi.org/10.1074/jbc.M202069200
8. Shinkawa T, Nakamura K, Yamane N, Shoji-Hosaka E, Kanda Y, Sakurada M, Uchida K, Anazawa H, Satoh M, Yamasaki M, et al. The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity. J Biol Chem 2003; 278:3466-73; PMID:12427744; http://dx.doi.org/10.1074/jbc.M210665200
9. Hristodorov D, Fischer R, Linden L. With or without sugar? (A)glycosylation of therapeutic antibodies. Mol Biotechnol 2013; 54:1056-68; PMID:23097175; http://dx.doi.org/10.1007/s12033-012-9612-x
10. Hessell AJ, Hangartner L, Hunter M, Havenith CE, Beurskens FJ, Bakker JM, Lanigan CM, Landucci G, Forthal DN, Parren PW, et al. Fc receptor but not complement binding is important in antibody protection against HIV. Nature 2007; 449:101-4; PMID:17805298; http://dx.doi.org/10.1038/nature06106
11. Hezareh M, Hessell AJ, Jensen RC, van de Winkel JG, Parren PW. Effector function activities of a panel of mutants of a broadly neutralizing antibody against human immunodeficiency virus type 1. J Virol 2001; 75:12161-8; PMID:11711607; http://dx.doi.org/10.1128/JVI.75.24.12161-12168.2001
12. Nimmerjahn F, Ravetch JV. Fcgamma receptors as regulators of immune responses. Nat Rev Immunol 2008; 8:34-47; PMID:18064051; http://dx.doi.org/10. 1038/nri2206
13. Simmons LC, Reilly D, Klimowski L, Raju TS, Meng G, Sims P, Hong K, Shields RL, Damico LA, Rancatore P, et al. Expression of full-length immunoglobulins in Escherichia coli: rapid and efficient production of aglycosylated antibodies. J Immunol Methods 2002; 263:133-47; PMID:12009210; http://dx.doi.org/10.1016/S0022-1759(02)00036-4
14. Chen X, Liu YD, Flynn GC. The effect of Fc glycan forms on human IgG2 antibody clearance in humans. Glycobiology 2009; 19:240-9; PMID:18974198; http://dx.doi.org/10.1093/glycob/cwn120
15. Millward TA, Heitzmann M, Bill K, Längle U, Schumacher P, Forrer K. Effect of constant and variable domain glycosylation on pharmacokinetics of therapeutic antibodies in mice. Biologicals 2008; 36:41-7; PMID:17890101; http://dx.doi.org/10.1016/j.biologicals.2007.05.003
16. Wright A, Morrison SL. Effect of altered CH2-associated carbohydrate structure on the functional properties and in vivo fate of chimeric mouse-human immunoglobulin G1. J Exp Med 1994; 180:1087-96; PMID:8064227; http://dx.doi.org/10.1084/jem.180.3.1087
17. Wright A, Sato Y, Okada T, Chang K, Endo T, Morrison S. In vivo trafficking and catabolism of IgG1 antibodies with Fc associated carbohydrates of differing structure. Glycobiology 2000; 10:1347-55; PMID:11159927; http://dx.doi.org/10.1093/glycob/10.12.1347
18. Newkirk MM, Novick J, Stevenson MM, Fournier MJ, Apostolakos P. Differential clearance of glycoforms of IgG in normal and autoimmune-prone mice. Clin Exp Immunol 1996; 106:259-64; PMID:8918571; http://dx.doi.org/10.1046/j. 1365-2249.1996.d01-847.x
19. Marian M, Harris R. The impact of Fc glycans on the clearance of Xolair. WCBP-congress 2002.
20. Close DR. Fixed single injection dosage for ocrelizumab (2h7). WO/2009/040268A1. 02 April 2009.
21. Adams CW, Grogan JL, Gurney AL, Mccutcheon K. Antibodies to lymphotoxin-alpha. WO/2008/063776A3. 05 March 2009.
22. Endl J, Eugui E, Fuentes M, Graus Y, Labrijn A, Lanzendoerfer M, Parren P, Rebers F, Schumacher R, Seeber S, Jan Van DW, Van VM. Anti-ox40l antibodies. Patent WO/2006/029879A2. 23 March 2006.
23. Kanda Y, Yamada T, Mori K, Okazaki A, Inoue M, Kitajima-Miyama K, Kuni-Kamochi R, Nakano R, Yano K, Kakita S, et al. Comparison of biological activity among nonfucosylated therapeutic IgG1 antibodies with three different N-linked Fc oligosaccharides: the high-mannose, hybrid, and complex types. Glycobiology 2007; 17:104-18; PMID:17012310; http://dx.doi.org/10.1093/glycob/ cwl057
24. Hötzel I, Theil FP, Bernstein LJ, Prabhu S, Deng R, Quintana L, Lutman J, Sibia R, Chan P, Bumbaca D, et al. A strategy for risk mitigation of antibodies with fast clearance. MAbs 2012; 4:753-60; PMID:23778268; http://dx.doi.org/10.4161/mabs.22189
25. Dall'Acqua WF, Kiener PA, Wu H. Properties of human IgG1s engineered for enhanced binding to the neonatal Fc receptor (FcRn). J Biol Chem 2006; 281:23514-24; PMID:16793771; http://dx.doi.org/10.1074/jbc.M604292200
26. Jacobsen FW, Padaki R, Morris AE, Aldrich TL, Armitage RJ, Allen MJ, Lavallee JC, Arora T. Molecular and functional characterization of cynomolgus monkey IgG subclasses. J Immunol 2011; 186:341-9; PMID:21131427; http://dx.doi.org/10.4049/jimmunol.1001685
27. Ng CM, Stefanich E, Anand BS, Fielder PJ, Vaickus L. Pharmacokinetics/ pharmacodynamics of nondepleting anti-CD4 monoclonal antibody (TRX1) in healthy human volunteers. Pharm Res 2006; 23:95-103; PMID:16308668; http://dx.doi.org/ 10.1007/s11095-005-8814-3
28. Bayliss TJ, Smith JT, Schuster M, Dragnev KH, Rigas Jr. A humanized anti-IL-6 antibody (ALD518) in non-small cell lung cancer. Expert Opin Biol Ther 2011; 11:1663-8; PMID:21995322; http://dx.doi.org/10.1517/14712598.2011.627850
29. Xiang H, Bender BC, Reyes AE 2nd, Merchant M, Jumbe NL, Romero M, Davancaze T, Nijem I, Mai E, Young J, et al. Onartuzumab (MetMAb): Using nonclinical pharmacokinetic and concentration-effect data to support clinical development. [Epub ahead of print]. Clin Cancer Res 2013; PMID:23894056; http://dx.doi.org/10.1158/1078-0432.CCR-13-0260
30. Ogura M, Tobinai K, Hatake K, Uchida T, Suzuki T, Kobayashi Y, Mori M, Terui Y, Yokoyama M, Hotta T. Phase I study of obinutuzumab (GA101) in Japanese patients with relapsed or refractory B-cell non-Hodgkin lymphoma. Cancer Sci 2013; 104:105-10; PMID:23046388; http://dx.doi.org/10.1111/cas.12040
31. Paz-Ares LG, Gomez-Roca C, Delord JP, Cervantes A, Markman B, Corral J, Soria JC, Bergé Y, Roda D, Russell-Yarde F, et al. Phase I pharmacokinetic and pharmacodynamic dose-escalation study of RG7160 (GA201), the first glycoengineered monoclonal antibody against the epidermal growth factor receptor, in patients with advanced solid tumors. J Clin Oncol 2011; 29:3783-90; PMID:21900113; http://dx.doi.org/10.1200/JCO.2011.34.8888
32. Fahrner RL, Knudsen HL, Basey CD, Galan W, Feuerhelm D, Vanderlaan M, Blank GS. Industrial purification of pharmaceutical antibodies: development, operation, and validation of chromatography processes. Biotechnol Genet Eng Rev 2001; 18:301-27; PMID:11530694; http://dx.doi.org/10.1080/02648725.2001.10648017
33. Wong AW, Baginski TK, Reilly DE. Enhancement of DNA uptake in FUT8-deleted CHO cells for transient production of afucosylated antibodies. Biotechnol Bioeng 2010; 106:751-63; PMID:20564613; http://dx.doi.org/10.1002/ bit.22749
34. Carter P, Presta L, Gorman CM, Ridgway JB, Henner D, Wong WL, Rowland AM, Kotts C, Carver ME, Shepard HM. Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci U S A 1992; 89:4285-9; PMID:1350088; http://dx.doi.org/10.1073/pnas.89.10.4285
35. Lu Y, Vernes JM, Chiang N, Ou Q, Ding J, Adams C, Hong K, Truong BT, Ng D, Shen A, et al. Identification of IgG(1) variants with increased affinity to FcγRIIIa and unaltered affinity to FcγRI and FcRn: comparison of soluble receptor-based and cell-based binding assays. J Immunol Methods 2011; 365:132-41; PMID:21185301; http://dx.doi.org/10.1016/j.jim.2010.12.014
36. Yang J, Ng C, Lowman H, Chestnut R, Schofield C, Sandlund B, Ernst J, Bennett G, Quarmby V. Quantitative determination of humanized monoclonal antibody rhuMAb2H7 in cynomolgus monkey serum using a Generic Immunoglobulin Pharmacokinetic (GRIP) assay. J Immunol Methods 2008; 335:8-20; PMID:18402977; http://dx.doi.org/10.1016/j.jim.2008.01.016
37. Loyet KM, Deng R, Liang WC, Wu Y, Lowman HB, DeForge LE. Technology comparisons for anti-therapeutic antibody and neutralizing antibody assays in the context of an anti-TNF pharmacokinetic study. J Immunol Methods 2009; 345:17-28; PMID:19345224; http://dx.doi.org/10.1016/j.jim.2009.03.012
38. Qiu ZJ, Ying Y, Fox M, Peng K, Lewin-Koh SC, Coleman D, Good J, Lowe J, Rahman A, Yang J, et al. A novel homogeneous Biotin-digoxigenin based assay for the detection of human anti-therapeutic antibodies in autoimmune serum. J Immunol Methods 2010; 362:101-11; PMID:20868690; http://dx.doi.org/10.1016/j. jim.2010.09.013
39. Peng K, Siradze K, Quarmby V, Fischer SK. Clinical immunogenicity specificity assessments: a platform evaluation. J Pharm Biomed Anal 2011; 54:629-35; PMID:21035975; http://dx.doi.org/10.1016/j.jpba.2010.09.035